Braveheart Bio

About us: Braveheart Bio is a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. Our lead product candidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin inhibitor (CMI) being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM). Braveheart’s goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, reversibility and reducing prescribing complexity. With a proven leadership team, a strong financial foundation, and a high-value late-stage asset, Braveheart Bio represents an outstanding opportunity for ambitious, mission-driven professionals to make a tangible impact in a high-profile and rapidly evolving therapeutic area. The role: Position reports to the Head of Medical Affairs. This individual will own the publications function for...

Own the global publication strategy for BHB-1893 across the evidence lifecycle. Serve as the central point of coordination for publications execution. Key Responsibilities: Develop and manage the integrated strategic publication plan and congress disclosures. Lead abstract, poster, and manuscript development for major cardiovascular meetings. Build publications infrastructure, SOPs, and oversee agency management. Qualifications: Advanced scientific degree plus 5-8+ years in publications or medical communications. Deep knowledge of GPP, ICMJE, clinical trial design, and publication platforms. Braveheart Bio is a clinical-stage biopharmaceutical company developing therapies for hypertrophic cardiomyopathy and other serious cardiovascular diseases. With a proven leadership team, strong financial foundation, and a late-stage asset, it offers mission-driven professionals a fast-paced and collaborative culture. #J-18808-Ljbffr